EZH2 amplification was first reported in hematologic malignancies [11,12], and there is increasing evidence showing that EZH2 is frequently overexpressed in a wide variety of cancerous tissue types, including endometrial, gastric, colon, esophageal, hepatocellular, bladder and oral cancers and is associated with poor prognosis [13,14,15,16,17,18]. This evidence concerns the gene EZH2 and hematologic disorder.